BNGO 📈 Bionano Genomics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09075F1075
BNGO: Software, Instruments, Chips, Reagents, Servers, Testing
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. Web URL: https://www.bionano.com
Additional Sources for BNGO Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BNGO Stock Overview
Market Cap in USD | 26m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2018-08-21 |
BNGO Stock Ratings
Growth 5y | -86.3% |
Fundamental | -5.19% |
Dividend | - |
Rel. Strength Industry | -1810 |
Analysts | 3/5 |
Fair Price Momentum | 0.14 USD |
Fair Price DCF | - |
BNGO Dividends
No Dividends PaidBNGO Growth Ratios
Growth Correlation 3m | -93.7% |
Growth Correlation 12m | -97.7% |
Growth Correlation 5y | -55.3% |
CAGR 5y | -54.64% |
CAGR/Mean DD 5y | -0.71 |
Sharpe Ratio 12m | -2.30 |
Alpha | -158.20 |
Beta | 3.04 |
Volatility | 86.30% |
Current Volume | 2511k |
Average Volume 20d | 3014.9k |
What is the price of BNGO stocks?
As of December 21, 2024, the stock is trading at USD 0.20 with a total of 2,511,041 shares traded.
Over the past week, the price has changed by -18.72%, over one month by -6.88%, over three months by -51.91% and over the past year by -87.96%.
As of December 21, 2024, the stock is trading at USD 0.20 with a total of 2,511,041 shares traded.
Over the past week, the price has changed by -18.72%, over one month by -6.88%, over three months by -51.91% and over the past year by -87.96%.
Is Bionano Genomics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Bionano Genomics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.19 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNGO as of December 2024 is 0.14. This means that BNGO is currently overvalued and has a potential downside of -30%.
Neither. Based on ValueRay Fundamental Analyses, Bionano Genomics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.19 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNGO as of December 2024 is 0.14. This means that BNGO is currently overvalued and has a potential downside of -30%.
Is BNGO a buy, sell or hold?
Bionano Genomics has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BNGO.
Bionano Genomics has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BNGO.
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecast for BNGO stock price target?
According to ValueRays Forecast Model, BNGO Bionano Genomics will be worth about 0.2 in December 2025. The stock is currently trading at 0.20. This means that the stock has a potential downside of -20%.
According to ValueRays Forecast Model, BNGO Bionano Genomics will be worth about 0.2 in December 2025. The stock is currently trading at 0.20. This means that the stock has a potential downside of -20%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1 | 400% |
Analysts Target Price | 13.2 | 6500% |
ValueRay Target Price | 0.2 | -20% |